Gemcitabine and nab-paclitaxel is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. Lead sponsors include Verastem, Inc. (1) and Orion Corporation, Orion Pharma (1). Registered phase: Phase 1/2. Conditions studied include KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212 (ClinicalTrials.gov ↗) Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer) |
Phase 1/2 | Recruiting |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| KRAS Activating Mutation | 1 |
| Metastatic Cancer | 1 |
| Pancreas Cancer | 1 |
| Neoplasms Pancreatic | 1 |
| Mesothelioma | 1 |
| Pancreatic Cancer | 1 |
| NSCLC (Advanced Non-small Cell Lung Cancer) | 1 |
| Lead sponsor | Trials |
|---|---|
| Verastem, Inc. | 1 |
| Orion Corporation, Orion Pharma | 1 |
| Register | Gemcitabine and nab-paclitaxel trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gemcitabine and nab-paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gemcitabine and nab-paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.